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abstract
PURPOSEMany institutions throughout the world have launched precisionmedicine initiatives in oncology, and a
large amount of clinical and genomic data is being produced. Although there have been attempts at data sharing
with the community, initiatives are still limited. In this context, a French task force composed of Integrated
Cancer Research Sites (SIRICs), comprehensive cancer centers from the Unicancer network (one of Europe’s
largest cancer research organization), and university hospitals launched an initiative to improve and accelerate
retrospective and prospective clinical and genomic data sharing in oncology.
MATERIALS AND METHODS For 5 years, the OSIRIS group has worked on structuring data and identifying
technical solutions for collecting and sharing them. The group used a multidisciplinary approach that included
weekly scientific and technical meetings over several months to foster a national consensus on a minimal data
set.
RESULTS The resulting OSIRIS set and event-based data model, which is able to capture the disease course, was
built with 67 clinical and 65 omics items. The group made it compatible with the HL7 Fast Healthcare In-
teroperability Resources (FHIR) format to maximize interoperability. The OSIRIS set was reviewed, approved by
a National Plan Strategic Committee, and freely released to the community. A proof-of-concept study was carried
out to put the OSIRIS set and Common Data Model into practice using a cohort of 300 patients.
CONCLUSIONUsing a national and bottom-up approach, the OSIRIS group has defined amodel including aminimal
set of clinical and genomic data that can be used to accelerate data sharing produced in oncology. Themodel relies
on clear and formally defined terminologies and, as such, may also benefit the larger international community.
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INTRODUCTION
Most national and international funding agencies
have acknowledged the importance of making clin-
ical and genomic data publicly available to obtain
enough information1 for correlative studies on bio-
markers associated with response to specific targeted
immunotherapies.
A large amount of cancer genomics data has been
provided to the scientific community through significant
national and international collaborations (ie, the CIT re-
search program,2 the Cancer Genome Atlas [TCGA],3
and the International Cancer Genome Consortium
[ICGC]4). Although these data sets are freely available,
researchers and clinicians face major obstacles using
them because of (1) a lack of standards regarding ge-
nomic data characterization and quality5 and (2) limited
clinical data in particular related to disease outcomes.
Despite these obstacles, the number of data sharing ini-
tiatives continues to grow. Several international data-
sharing networks have recently emerged to help re-
searchers get access to clinical and genomic data in ge-
nomic cancer medicine. For examples, international
networks such as PCORnet,6 OHDSI Research Network,7
GENIE,8 BRCA Exchange from GA4GH7,9 CancerLinQ,10
ORIEN,11 and ICGCARGO,12 andEuropeannetworks such
as Europe lung cancer data collection13 and the German
Cancer Consortium (DKTK)14 are some important initiatives
in this field. Although such initiatives are interesting, access
to full data is restricted to consortium members or lacks
relevant clinical information to link genomic alterations with
clinical benefit under specific drugs.
Between 2011 and 2013, precision medicine was
becoming pervasive and Integrated Cancer Research
(SIRICs) sites in France conducted molecular profiling
clinical trials (eg, SHIVA, MOSCATO, and ProfiLER).
These clinical trials meant a radical paradigm shift by
providing innovative therapies guided by genomic
alterations identified in a tumor. The idea in 2013 was
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critical number of patients, which would enable a mean-
ingful analysis. To empower the joint analysis of these trials,
a common minimal data set along with a Common Data
Model (CDM) was needed to reach our goal. We wanted a
CDM to be modular, limited in size and agile, extensible
beyond clinical and genomic data, and able to capture the
longitudinal changes associated with disease progression
and resistance to therapeutic interventions.
In this context, the OSIRIS (Interoperability and data
sharing of clinical and biological data in oncology)
initiative15 was launched in 2015 to address data hetero-
geneity with four major commitments: (1) using a bottom-
up approach by keeping the OSIRIS set as minimal as
possible, (2) reaching a national consensus from all
stakeholders involved in cancer research, (3) using inter-
nationally established terminologies as much as possible,
and finally (4) defining implementation rules to guarantee
data consistency of the OSIRIS set across institutions.
A French national task force composed of Comprehensive
Cancer Centers from the Unicancer network,16 University
Hospitals, and the eight SIRICs was formed under the
auspices of the French Institut National du Cancer (INCa).17
Herein, we propose a minimum set of clinical and genomic
data relevant to the field of precision medicine in oncology, a
data model that allows us to capture the disease course,
including therapy response and toxicity. OSIRIS was com-
pared with other similar initiatives such as mCODE18 and
OMOP19 and was tested in a set of 300 patients included in
six different multicentric studies as a proof-of-concept.
MATERIALS AND METHODS
CDM: Identification of the Data Concepts
The goal of the CDM was to share a set of standardized,
extensible data concepts (eg, patient, tumor events, treatment,
response evaluation, and adverse event) that enabled con-
sistency of both data and their meaning across applications.
The group focused its efforts on (1) providing a comprehensive
resource of cancer event–based data and their temporal re-
lationships, that is, to help clinicians discover longitudinal
changes associated with disease progression and resistance to
therapeutic interventions; (2) creating a modular and exten-
sible data model, that is, to integrate omics data from different
experiments on the same samples (vertical integration) or
across studies on the same variables (horizontal integration);
and (3) creating the technical conditions for interoperability.
Minimum Data Set: Standardization and Interoperability
of the Data Elements
A data set was defined as a collection of variables, such as
the gender and age of a patient, with a list of possible values
for each of them. Each variable is called a Data Element (DE),
and the list of possible values a Code List (CL). To define a
minimum set of valuable DEs at the national level, our ap-
proach was based on the following steps: (1) identifying the
most relevant items based on a 2015 Institut Curie data
model, the experience of the Unicancer network of com-
prehensive cancer centers with Consore,20,21 the case report
forms of precision medicine clinical trials promoted by
participating institutions, and the national database
Conticabase22-27; (2) extracting the DEs of those clinical
trials; (3) identifying and comparing the most relevant DEs;
and finally, (4) standardizing the CLs of the Common Data
Elements (CDEs) using appropriate international terminol-
ogies when possible (Fig 1). To ensure the accuracy and
quality of data collected through the different studies, the
OSIRIS group used an adapted data collection strategy that
focused on a limited number of mandatory CDEs to facilitate
structured data extraction and limit missing data.
Identification of French Genomic-Driven Clinical Trials
and National Databases and Extraction of the DEs
Major clinical trials were conducted in France28 using tar-
geted sequencing to identify actionable alterations and
CONTEXT
Key Objective
How can we improve standardization of clinical and genomic data to improve data sharing and interoperability by capturing the
disease course in the context of precision medicine in Oncology?
Knowledge Generated
We propose an event-based data model of a minimal set of clinical and genomic items using international standards and
terminologies enabling a strong interoperability. OSIRIS common data model is modular and extensible to other types of
data.
Relevance
OSIRIS was developed in the context of large precision medicine clinical trials to incorporate the longitudinal changes
associated with disease progression and resistance to therapeutic interventions. It could also provide an effective real-world
data ecosystem by developing a data standard, which, if used, could improve the compatibility, quality, and consistency of
electronic health record. In both cases, OSIRIS may facilitate the application of artificial intelligence and enhance su-
pervised machine learning and data science in the context of clinical care and clinical research.
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assign therapy to patients with refractory cancers. Data from
these clinical trials are of high quality but sorely lack the
standards to enable data sharing across institutions. Six
broad clinical trials (Table 1) were selected as a case study to
extract the DEs.
Identification and Comparison of the Most Relevant DEs
To define a set of CDEs representing a minimal data set to
answer scientific and medical questions, the OSIRIS group
used a multidisciplinary approach including oncologists,
medical informatics specialists, bioinformaticians, epide-
miologists, biostatisticians, and regulatory specialists in
iteration planning meetings. This method provided different
perspectives and prompted extensive discussions to select
the most relevant DEs.37 After a year of weekly iteration
meetings, the OSIRIS group reached a consensus.
Validation of the CDE
A national board composed of clinicians and translational
researchers in oncology and data protection officers first
examined whether the CDEs were compliant with the
General Data Protection Regulation38 and the National
Commission for Data Protection and Liberties (CNIL-
France).39 They oversaw the centralization of common sci-
entific questions from different medical specialties and
cancer pathologies (eg, identification of actionable genomic
alterations, identification of rare recurrent genetic alterations,
and understanding genetic trajectories). Common scientific
questions that emerged can be classified into three broad
categories: (1) clinical and biological cohorts, (2) descriptive
and functional translational studies, and (3) interventional
clinical trials. Then, national board proceeded to ensure that
the OSIRIS CDEs could answer those questions.
Standardizing the CLs of the CDE
CL standardization was a prerequisite step to ensure greater
interoperability of the OSIRIS set. A technical board
composed of bioinformaticians and data managers was
responsible for identifying the most relevant international
and national terminologies (eg, CCAM code of the medical
act). Most of the CDEs were mapped to these terminologies
(Table 2). For some CDEs, the group created its own
Extraction of relevant data elements
Validation of the set OSIRIS v1
with a set of scientific questions 
Production set OSIRIS version v1.1.05
SIRIC network
An existing set  of data structures
European tumor databases
(eg, Conticabase)












Set OSIRIS version v1 
Every week/16 weeks
FIG 1. The overall methodology used to deliver the first release of the OSIRIS set. During several months, weekly meetings of several
national groups (SIRIC multidisciplinary group and scientific and technical boards) were held to release the first version of the OSIRIS
set. SIRIC, Integrated Cancer Research Sites.
Guérin et al
258 © 2021 by American Society of Clinical Oncology
Downloaded from ascopubs.org by 92.158.209.212 on April 20, 2021 from 092.158.209.212
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
terminologies for terms that did not have yet a common
standard definition (eg, biomarker code, sample origin, and
panel name). Genomic CDEs were based on Fast
Healthcare Interoperability Resources (FHIR) v3 genomic
items when available (eg, AminoAcidChange, DNAR-
egionName, and GenomicSourceClass).
Validation of the OSIRIS Set
To validate this approach, the group federated retrospective data
to assess a first cohort of 300 patients included in six clinical
trials. Minor functional changes, such as modifying a CDE or
supplementing a CL, were needed to strengthen the model.
RESULTS
OSIRIS CDM
A first version of the CDM (v1) was released in 2018,40
which formed the basis of discussion for the SIRIC
multidisciplinary scientific meetings and, later, for the
technical board meetings. Several institutions tested the
model (ie, completeness level and inconsistency rate), and
the group proposed and implemented substantial revisions
through functional analysis and data integration feedback.
This helped establish a reliable, robust, and comprehensive
model to describe cancer. Figure 2 shows the clinical data
model with the CDEs and the relationships between them.
Given that health data change over time, the OSIRIS group
focused its efforts on modeling an event-based temporal
data model. Each DE of the OSIRIS CDM is linked to a
particular TumorPathologyEvent (TPE) (ie, Primary, Re-
current, and Metastatic tumor) concept. Each TPE occurs
not only over a period of time but also relative to the time of
another TPE to follow the course of the disease precisely.
Patient follow-up represented on a timeline (ie, Analysis
and Treatment concepts) is another key element of the
TABLE 1. List of the Clinical Trials Used to Extract DEs
NCT Number Title Acronym Type of Tumor
No.
Patients
NCT0253464929 Fighting cancer by matching molecular alterations and drugs in early
phase trials
BIP Locally advanced or
metastatic cancer
4,500
NCT0177440930 Program to establish the genetic and immunologic profile of patient’s tumor for
all types of advanced cancer
ProfiLER31 All types of advanced
cancer
4,357
NCT0156601932 Molecular screening for cancer treatment optimization MOSCATO Any cancer in the
metastatic phase
2,150
NCT0229999933 SAFIR02_Breast—Efficacy of genome analysis as a therapeutic decision tool






NCT0177145834 A randomized phase II trial comparing therapy based on tumor molecular
profiling versus conventional therapy in patients with refractory cancer
SHIVA35 All refractory tumors 742
NCT0234215836 Identifying molecular alterations to guide individualized treatment in
advanced solid tumors
PERMED01 Locally advanced or
metastatic cancer
460
NOTE. This table describes the clinical trials of precision medicine through molecular profiling initiated by the organization centers of the OSIRIS group.
These studies were used to extract, compare, and select the data elements, a necessary precondition for defining the OSIRIS set and its event-based data
model.
Abbreviation: DE, data element.
TABLE 2. Main International and National Terminologies Used in the OSIRIS Set
Data Domain National and International Ontologies and Terminologies
Patient characteristics Fast Healthcare Interoperability Resources (FHIR, 3rd edition)
Unified Medical Language System (UMLS)
WHO classification (performance status)
Disease characteristics International Classification of Disease for Oncology (ICD-O-3, 3rd edition)
International Statistical Classification of Diseases and Related Health Problems (ICD, 10th edition)
UICC TNM Classification of Malignant Tumors
Drug Anatomical Therapeutic Chemical Classification System (ATC, 5th level)
Adverse events Common Terminology Criteria for Adverse Events (CTCAE, 5th edition)
Response evaluation RECIST, version 1.1
Medical act Classification of the French Social Security (National Health Service)
Genomic concepts Logical Observation Identifiers Names and Codes (LOINC)
HL7 Fast Healthcare Interoperability Resources (HL7 FHIR)
NOTE. The OSIRIS set relies on international and national terminologies to facilitate interoperability with other common data models. For each data domain
(eg, Patient and Disease characteristics), we use one or more terminologies when necessary.
OSIRIS: Data Set for Data Sharing and Interoperability in Oncology
JCO Clinical Cancer Informatics 259
Downloaded from ascopubs.org by 92.158.209.212 on April 20, 2021 from 092.158.209.212
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
model, and derived concepts such as AdverseEvent,
ResponseEvaluation, and Biomarker are also included.
Rules were defined when the time of a TPE is incomplete or
uncertain by looking at the timeline of the follow-up care
plan. This provides a high-quality OSIRIS-formatted data
set required for training machine learning models to ad-
dress questions like relapse prediction and covers the
necessary topics for patient similarity identification.41 To
date, the model covers the description of solid tumors and
minor changes will be needed to handle hematological
tumors.
Genomics is an integral component and is considered as a
separate and distinct type of analysis in the data model as
shown in Figure 3. All analysis concepts are linked to the
clinical model using the TumorPathologyEvent concept as
a key component. Some concepts define the analysis itself
to ensure reproducibility, tracking provenance, and context
of the results (ie, sequencing technology, target panel, and
bioinformatics pipeline including analysis parameters),
whereas others give a confidence level of the predictions
(ie, validation) or variant annotation for cancer diagnosis (ie,
annotation). The AlterationOnSample class is an umbrella
concept of shared attributes common to the different types
of genomic alterations. Entities related to this generic
concept enable the storage of specific alteration data type.
To date, the data model covers copy number alterations,
fusions, gene expression data, and somatic mutations. The
flexibility of the model is a major asset to easily add new
omics data (eg, epigenetic and proteomic data) that will
allow multiomics layer integration.
The OSIRIS Set
Once the OSIRIS set reached a steady state in terms of its
semantic content, a first version (1.1.05) was released in
February 2019. This current release, built on an event-
based data model, describes a minimum data set that
allows capture of the disease course longitudinally. This
release, freely available to the community on GitHub,42
consists of a minimal data set of 67 clinical and 65
omics items (described in the Data Supplement) required
and validated by the national scientific board. CLs are
based on international and national terminologies, com-
plemented by their own terminologies for terms that do not
yet have a common standard definition. The Data Sup-




Family Cancer History Related Pathology
Treatment
















































Clinical or omics linking 
  item
CLINICAL MODEL
FIG 2. OSIRIS clinical data model. This figure shows the OSIRIS event–based clinical data model to follow the disease course longitudinally. For each
event type (primary tumor and local and metastatic relapse), the response and adverse events of a treatment are associated. Moreover, any analysis
carried out on a sample (imaging, omics, biology, pathologic examination) is also linked to a specific event.
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As a proof-of-concept, clinical and genomic data from 300
patients included in six different clinical trials were used to
allow basic descriptive statistics. As a result of these sta-
tistics, there is much heterogeneity of the clinical CDEs
being used within each clinical trial. Some clinical concepts
are well represented (ie, Patient, BiologicalSample,
TumorPathologyEvent, Treatment, AdverseEvent, and
Drug), whereas others are hardly used (ie, Family-
CancerHistory and RelatedPathology). By comparing the
CDE terminologies, substantial clinical differences were
found. For instance, some French pathologists rely on a
national multiaxial terminology (Association pour le
De ́veloppement de l’Informatique en Cytologie et Anatomie
Pathologique, ADICAP), whereas others use the interna-
tional standard ICD-O-3 (International Classification of
Diseases for Oncology) to standardize pathology reports.
Translating ADICAP codes to ICD-O-3 was necessary, and a
quality control program was applied to assess data quality,
correcting errors and adding missing data. All the clinical
trials used targeted next-generation sequencing (NGS) as a
tool for precision medicine, which ensured the consistent
use of the genomic concepts. Variability in genomic data
reporting was observed, rooted in the wide variety of NGS
technologies and analysis tools with no emphasis on in-
teroperability. Genetic reports provided by the different
stakeholders often result in a partial or heterogeneous
description of genomic alterations (eg, the reference se-
quence of single nucleotide variants is not always properly
reported). We noted as well a variability of the metadata that
add further clinical interpretation of variants (ie, cross-
references to external databases and precomputed
in silico algorithm-based predictions). To ensure the sus-
tainability, expandability, and interoperability of the OSIRIS
set with other systems, the first release was made com-
patible with the growing health information exchange
standard HL7 FHIR in June 2020. For instance, the ge-
nomic CDM was mapped to FHIR v4 genomic resources.














































FIG 3. OSIRIS omics data model. Thanks to an object-oriented model, the omics concepts were designed to be scalable and modular. The model uses
inheritance to store common (ie, AlterationOnSample concept) and specific attributes of various kinds of genomic alterations. Each genomic alteration is
annotated for cancer diagnosis (ie, Annotation concept) along with the confidence level of the prediction (ie, validation concept).
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annotating data with external repositories and the existing
resources such as Observation. In the Data Supplement,
OSIRIS was compared with other similar initiatives such as
mCODE and OMOP.
List of Structured Flat Files to Share Data
To share the OSIRIS set, each participating institution
generated a list of structured flat files in comma separated
format (“.csv”). The layout, content, and coding of eighteen
flat files were standardized43 to structure data in each
center. The flat files follow the relational OSIRIS CDM to be
directly interoperable with any third-party software and
readable by the clinicians. By providing a single entry
point, any data source can be processed and represented
in our data model (described in Appendix Fig A1). For
instance, we used these files to store real-world data
(RWD) either to complete the OSIRIS set for clinical data
(ie, FamilyCancerHistory and RelatedPathology concepts)
or to integrate genomics data not used to guide targeted
therapy. To ensure the correct use of the CDEs, OSIRIS
users must follow the DE specification guideline and carry
out the necessary checks to guarantee compliance
therewith.44
DISCUSSION
Within the context of the SIRIC efforts and supported by
INCa, a need to enhance data sharing in genomic-driven
clinical trials to clinicians and translational researchers was
identified. The OSIRIS project emerged in 2015 to find
creative, technological, and regulatory solutions for im-
proving standardization and data sharing at the national
level.
We identified common challenges to promote data sharing
in precision medicine,45 which led to the constitution of
three working groups (ie, regulatory and data policy, data
standards, and technical data sharing solutions). Gover-
nance required transparent decision making, and this
transparency offers a constructive basis for engagement
with new institutions.
The group emphasized the value of data collected within
the context of clinical trials and beyond. For example, ar-
tificial intelligence (AI) projects have emerged over the past
few years and rely heavily on standardized data sets to train
and validate statistical models, which could be provided by
the OSIRIS data set. Moreover, OSIRIS provides an effective
RWD ecosystem by developing a data standard, which, if
used, could improve the compatibility, quality, and con-
sistency of Electronic Health Record.
The OSIRIS set is a useful standardization tool for clinical
cancer research data within the SIRIC research network.
Since it relies on already established terminologies, it may
also be useful within the context of a larger international
community across different networks. In addition, the
OSIRIS set greatly facilitates data model harmonization and
data integration with other repositories. At an international
level, data interoperability in health care is a major chal-
lenge and some standards have emerged such as FHIR
(Fast Healthcare Interoperability Resources).45 FHIR is the
latest HL7 (Health Level 7’s) healthcare data representation
standard for data exchange by (1) using established code
sets (eg, LOINC, SNOMED CT, and ICD-9/-10) or (2) FHIR-
specific value sets to maximize standardization. Moreover,
FHIR offers the ability for individual users and organizations
to build extensions to capture data that are not explicitly
defined by HL7.46 Accordingly, the group adopted its data
model to bring it in line with this international standard. We
profiled the overlap and gaps between the OSIRIS schema
(version 1.1.05) and the corresponding FHIR resources
(version 4.0.1).
The main values of the OSIRIS set and its event-based
data model are the following: (1) a minimum data set
organized as a temporal model of cancer events enabling
the data longitudinal search; (2) an original blend of
clinical and omics concepts; (3) a data model designed to
be scalable and modular to integrate other specific ter-
minology aspects according to localization, treatment (eg,
radiation therapy), and other types of biological and omics
analysis (eg, proteomic); and (4) the OSIRIS set that relies
mostly on international terminologies. Some limitations
remain and must be addressed by the OSIRIS group. For
instance, OSIRIS does not provide data quality checks of
these files that could be run against an OSIRIS CDM in-
stance. In 2019, OMOP developed a Data quality
Dashboard47 based on the Kahn Framework, which uses a
system of categories and contexts that represent strate-
gies for assessing data quality. This framework could be
used to provide quality metrics as (1) conformity of the
OSIRIS CDM specifications and (2) level of completeness
of the OSIRIS set. Another limitation of OSIRIS is the lack
of procedure to follow the different versions of the ter-
minologies used. This task is necessary to reproduce
different analysis done on different versions of the OSIRIS
set. Versioning the data for reproducible analysis is not an
easy task in a fast-moving field, which requires ongoing
updating and comparison of the different versions. To
ensure the dissemination of the OSIRIS set, INCa pro-
motes its use in clinical trials and data sharing projects
(eg, React-4kids network) that they fund. The OSIRIS set
may also be useful in projects involving healthcare data
storage and retrieval (eg, Health Data Hub48 and in the
French Genomic Medicine Plan 202549 as part of the Data
Collector and Analyzer).
To date, the OSIRIS consortium is working on (1) the set
and CDM’s evolution, (2) improved interoperability with
international standards (eg, OMOP), and finally (3) training
support and advice to all stakeholders interested in using
the OSIRIS set.
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3INSERM U1218—ACTION Unit, Bordeaux, France
4Synergie Lyon Cancer, Platform of Bioinformatics Gilles Thomas, Centre
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5286, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France
20Department of Medical Oncology, Centre Léon Bérard, Lyon, France
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Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF
INTEREST
The following represents disclosure information provided by authors of
this manuscript. All relationships are considered compensated unless
otherwise noted. Relationships are self-held unless noted. I = Immediate
Family Member, Inst = My Institution. Relationships may not relate to the
subject matter of this manuscript. For more information about ASCO’s
conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.
org/cci/author-center.
Open Payments is a public database containing information reported by
companies about payments made to US-licensed physicians (Open
Payments).
Vincent Le Texier
Travel, Accommodations, Expenses: Roche/Genentech
Sophie Gourgou
Consulting or Advisory Role: Celgene, Roche
Elisabeth Hess
Stock and Other Ownership Interests: Sanofi, GENFIT, Innate Pharma
Pierre Saintigny
Honoraria: HTG Molecular Diagnostics, Inivata, Archer, Bristol-Myers
Squibb, Roche Molecular Diagnostics
Research Funding: Roche, AstraZeneca, Novartis, Bristol-Myers Squibb
Travel, Accommodations, Expenses: Illumina, Bristol-Myers Squibb,
AstraZeneca, Roche
No other potential conflicts of interest were reported.
ACKNOWLEDGMENT
The authors thank the patients included in the clinical trials used in the
proof of concept. OSIRIS acknowledges the eight SIRICs (Integrated
Cancer Research Site) funded by INCa, DGOS, and Inserm.
REFERENCES
1. Lawrence MS, Stojanov P, Mermel CH, et al: Discovery and saturation analysis of cancer genes across 21 tumor types. Nature 505:495–501, 2014
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APPENDIX

































FIG A1. Description of the use of the OSIRIS structured flat files. We use the OSIRIS flat files as an entry point to standardize data from different data
sources (ie, EHRs, eCRFs, data warehouses, and cancer registries). These pivot files are then used to facilitate interoperability with other standards. For
instance, we used them to construct ETLs with I2B2 CDM instances and the FHIR API. API, application programming interface; CDM, Common Data
Model; EHR, Electronic Health Record; ETL, extract, transform, and load; FHIR, Fast Healthcare Interoperability Resources.
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